{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:33:00Z","timestamp":1792751580611,"version":"4.5.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer incidence and mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs), particularly those targeting the programmed cell death protein 1\/programmed death-ligand 1 (PD-1\/PD-L1) axis, have significantly improved survival outcomes in a subset of patients. However, the magnitude and durability of clinical benefit vary considerably according to PD-L1 expression, treatment setting, histological subtype, oncogenic driver status, and whether ICIs are administered as monotherapy or in combination regimens. A substantial proportion of patients therefore exhibit either primary resistance or acquired resistance after an initial response. This review systematically summarizes the key mechanisms underlying immune resistance in lung cancer. These include defects in antigen presentation, such as abnormalities in major histocompatibility complex class I (MHC-I), transporter associated with antigen processing 2 (TAP2), and \u03b22-microglobulin (B2M), as well as dysregulation of the interferon-\u03b3\/Janus kinase-signal transducer and activator of transcription (IFN-\u03b3\/JAK-STAT) signaling pathway. Tumors frequently exhibit an immune-excluded or \u2018cold\u2019 phenotype, which further limits immune recognition and reduces responsiveness to immunotherapy. This review summarizes immune resistance in NSCLC through a framework that distinguishes primary resistance from acquired resistance. Primary resistance reflects failure of immune activation at treatment initiation, usually due to pre-existing tumor-intrinsic or microenvironmental barriers, including impaired antigen presentation, defective IFN-\u03b3\/JAK-STAT signaling, low tumor immunogenicity, immune-cold or immune-excluded phenotypes, and suppressive TME states. In contrast, acquired resistance reflects adaptive tumor and immune ecosystem evolution under therapeutic pressure, leading to neoantigen loss, HLA or B2M alterations, compensatory checkpoint activation, progressive T cell exhaustion, TME remodeling, and epigenetic stabilization of immune escape. We further discuss mechanism-based biomarkers, translational correlates, and rational therapeutic strategies for overcoming resistance.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1864819","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:36:16Z","timestamp":1783575376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary and acquired resistance to immunotherapy in NSCLC"],"prefix":"10.3389","volume":"17","author":[{"given":"Bo","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Spine Surgery, Hunan Aerospace Hospital, The Affiliated Aerospace Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qujing Hospital of Traditional Chinese Medicine","place":["Qujing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulin","family":"Jiang","sequence":"additional","affiliation":[{"name":"College of Life Science, University of Chinese Academy of Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Hunan Aerospace Hospital, The Affiliated Aerospace Hospital of Hunan Normal University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: Epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clinics Chest Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.12.006","article-title":"Lung cancer","volume":"103","author":"Nasim","year":"2019","journal-title":"Med Clinics North America"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"Morrison","year":"2018","journal-title":"Trends Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq7248","article-title":"Cancer immunotherapy by \u03b3\u03b4 T cells","volume":"386","author":"Hayday","year":"2024","journal-title":"Sci (New York NY)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104295","article-title":"The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: The challenge is open for new therapeutic strategies","volume":"196","author":"Ferro","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03731-x","article-title":"Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC","volume":"27","author":"Gomatou","year":"2025","journal-title":"Clin Trans Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101266","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist Upd: Rev Commentaries Antimicrob Anticancer Chemother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (review)","volume":"59","author":"He","year":"2021","journal-title":"Int J Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.critrevonc.2026.105411","article-title":"Immunotherapy resistance in non-small cell lung cancer: From mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/english\/efy035","article-title":"CD8(+) T cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-024-01618-6","article-title":"NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-025-02285-y","article-title":"NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer","volume":"24","author":"Dai","year":"2025","journal-title":"Mol Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-025-02276-z","article-title":"IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer","volume":"24","author":"Ranjan","year":"2025","journal-title":"Mol Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: An overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukocyte Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/08830180902978120","article-title":"Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation","volume":"28","author":"Zhou","year":"2009","journal-title":"Int Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218219","article-title":"HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8(+) T cell glutamine metabolism via KIR3DL3 interaction","volume":"639","author":"Wu","year":"2026","journal-title":"Cancer Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02191-9","article-title":"Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response","volume":"24","author":"Jenkins","year":"2025","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun (Lond Engl)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/mTOR signaling pathway: An important driver and therapeutic target in triple-negative breast cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer (Tokyo Japan)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-013-9385-0","article-title":"CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function","volume":"10","author":"Lee","year":"2014","journal-title":"Purinergic Signall"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","article-title":"TGF-\u03b2 signaling in health, disease, and therapeutics","volume":"9","author":"Deng","year":"2024","journal-title":"Signal Transd Targ Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1177\/239693937800200110","article-title":"Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy","volume":"41","author":"Escobar","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nat Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0427-6","article-title":"PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-15","volume":"18","author":"Kim","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: Opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4817","article-title":"Restoring tumor immunogenicity with dendritic cell reprogramming","volume":"8","author":"Zimmermannova","year":"2023","journal-title":"Sci Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.cell.2024.03.019","article-title":"ITPRIPL1 binds CD3\u03f5 to impede T cell activation and enable tumor immune evasion","volume":"187","author":"Deng","year":"2024","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00776-z","article-title":"A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging","volume":"5","author":"Iltis","year":"2025","journal-title":"Nat Aging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17474086.2024.2370552","article-title":"T-cell exhaustion in multiple myeloma","volume":"17","author":"\u017by\u0142ka","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216043","article-title":"CD8(+) T cell exhaustion and cancer immunotherapy","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13046-024-03122-8","article-title":"CXCL5 impedes CD8(+) T cell immunity by upregulating PD-L1 expression in lung cancer via PXN\/AKT signaling phosphorylation and neutrophil chemotaxis","volume":"43","author":"Sun","year":"2024","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: Unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: Key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01067-4","article-title":"Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer","volume":"48","author":"Zhao","year":"2025","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-025-01673-2","article-title":"Lactate dehydrogenase B facilitates disulfidptosis and exhaustion of tumour-infiltrating CD8(+) T cells","volume":"27","author":"Wan","year":"2025","journal-title":"Nat Cell Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2024-0648oc","article-title":"HDLBP promotes glycolysis and CD8(+) T cell exhaustion in lung adenocarcinoma by stabilizing GJB2 RNA","volume":"73","author":"Xu","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13073-023-01164-9","article-title":"Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing","volume":"15","author":"Hu","year":"2023","journal-title":"Genome Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1038\/s41467-025-64839-4","article-title":"Cancer cell-derived IL-1\u03b2 reverses chemo-immunotherapy resistance in non-small cell lung cancer","volume":"16","author":"Perrichet","year":"2025","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401399","article-title":"Lactylation-driven IGF2BP3-mediated serine metabolism reprogramming and RNA m6A-modification promotes lenvatinib resistance in HCC","volume":"11","author":"Lu","year":"2024","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2019.07.011","article-title":"Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance","volume":"94","author":"Ponnusamy","year":"2020","journal-title":"Adv Clin Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.124.324455","article-title":"Genome-wide methylation analysis reveals a KCNK3-prominent causal cascade on hypertension","volume":"135","author":"Huang","year":"2024","journal-title":"Circ Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13238-021-00846-7","article-title":"Metabolic reprogramming and epigenetic modifications on the path to cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Protein Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/jci193162","article-title":"USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I","volume":"136","author":"Liu","year":"2026","journal-title":"J Clin Invest"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102633","article-title":"Dual PD-1\/IL-2R\u03b1 targeting restores CD8(+) T cell fitness via STAT5\/CD47 axis in SMARCA4-deficient NSCLC","volume":"7","author":"Shang","year":"2026","journal-title":"Cell Rep Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-0065","article-title":"METTL14 enhances antitumor immunity through m6A-dependent loss of PD-1","volume":"85","author":"Huang","year":"2025","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1454","article-title":"Multidimensional immunotyping of human NF1-associated peripheral nerve sheath tumors uncovers tumor-associated macrophages as key drivers of immune evasion in the tumor microenvironment","volume":"30","author":"Zhang","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc For Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac063","article-title":"Tumor mutational burden measurement using comprehensive genomic profiling assay","volume":"52","author":"Kage","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2019.04.003","article-title":"Antigen presentation by dendritic cells for B cell activation","volume":"58","author":"Heath","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.11.018","article-title":"Circulating tumor DNA assessment for gynaecological cancers management","volume":"106","author":"Mari","year":"2019","journal-title":"Bull du Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2022.09.010","article-title":"Circulating tumor cells and circulating tumor DNA in urologic cancers","volume":"50","author":"Madueke","year":"2023","journal-title":"Urologic Clinics North America"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.028406","article-title":"Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring","volume":"31","author":"Alemzadeh","year":"2023","journal-title":"Oncol Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.04.020","article-title":"Brief report: Safety and antitumor activity of durvalumab plus tremelimumab in programmed cell death-(ligand)1-monotherapy pretreated, advanced NSCLC: Results from a phase 1b clinical trial","volume":"18","author":"Garon","year":"2023","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/cancers15112912","article-title":"Chemo-immunotherapy: A new trend in cancer treatment","volume":"15","author":"Sordo-Bahamonde","year":"2023","journal-title":"Cancers"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413387","article-title":"Verteporfin-mediated in situ nanovaccine based on local conventional-dose hypofractionated radiotherapy enhances antitumor and immunomodulatory effect","volume":"12","author":"Zhang","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","article-title":"YTHDF2 inhibition potentiates radiotherapy antitumor efficacy","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207608","article-title":"Metabolic intervention liposome boosted lung cancer radio-immunotherapy via hypoxia amelioration and PD-L1 restraint","volume":"10","author":"Wang","year":"2023","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci153167","article-title":"Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-\u03b3-stimulated antitumor immunity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1177\/15330338251406931","article-title":"Combining radiation and anti-PD-L1 enhances the antitumor activity in colorectal cancer via IFN-\u03b3-dependent activation of STAT1","volume":"24","author":"Yang","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109993","article-title":"Triptolide reduces PD-L1 through the EGFR and IFN-\u03b3\/IRF1 dual signaling pathways","volume":"118","author":"Xie","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08466-x","article-title":"Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted","volume":"639","author":"Reina-Campos","year":"2025","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11912-020-00983-y","article-title":"Alternative checkpoints as targets for immunotherapy","volume":"22","author":"Pant","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8(+) T cell exhaustion","volume":"26","author":"Sun","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501238","article-title":"NDRG1-driven lactate accumulation promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment","volume":"12","author":"Wu","year":"2025","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-22-1890","article-title":"Stromal reprogramming through dual PDGFR\u03b1\/\u03b2 blockade boosts the efficacy of anti-PD-1 immunotherapy in fibrotic tumors","volume":"83","author":"Akiyama","year":"2023","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864819\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:36:17Z","timestamp":1783575377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1864819\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2026.1864819"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1864819","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1864819"}}